BiotechTube
DiNAQOR

DiNAQOR

Zurich, Germany· Est.
dinaqor.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

DiNAQOR is a Swiss-based life science company builder specializing in creating and scaling biotechnology ventures, with a focus on gene therapy and advanced delivery platforms. The company has established a spin-out, DiNATEQ AG, to clinically translate its proprietary closed-loop loco-regional perfusion (LRP) delivery technology. Recent strategic leadership appointments, including the CEO of Sirion Biotech, underscore its intent to build strategic partnerships and translate breakthrough technologies into clinical and commercial success.

RNA & Gene TherapyViral Technology

Technology Platform

Closed-loop loco-regional perfusion (LRP) delivery platform for targeted, localized therapeutic delivery, particularly for gene therapies.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The platform addresses a critical bottleneck in gene therapy—targeted delivery—opening a large market.
The company-builder model allows for portfolio diversification and multiple value-creation points through spin-outs and partnerships.

Risk Factors

High technical risk associated with novel delivery platform; unproven clinical efficacy.
Financial risk as a pre-revenue company dependent on external funding.
Execution risk in managing multiple early-stage ventures.

Competitive Landscape

Competes in the crowded and innovative field of targeted drug/gene delivery. Faces competition from other platform companies (e.g., lipid nanoparticle developers, other viral vector engineers) and large pharma internal R&D. Differentiation hinges on clinical proof of LRP's advantages.

More companies in RNA Therapeutics (non-mRNA) →More companies in Germany →